Riskpilot← Back to searchSign inGet full accessLillyVet AB
ABActiveOrg 5569320400Tulegatan 12Veterinary activities · NACE 7500Est. 20131 employees
Revenue 2024
SEK 0
EBITDA margin
—
+77% vs 2023
Equity ratio
61.2%
Financial strength
Net profit 2024
SEK -14K
+79% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -14K | +77% |
| Net profit | SEK -14K | +79% |
| Total assets | SEK 85K | -17% |
| Equity | SEK 52K | +2% |
| Employees | 1 | — |
Legal name
LillyVet AB
Org number
5569320400
Legal form
Aktiebolag
NACE code
7500 · Veterinary activities
Founded
17 maj 2013
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolagets verksamhet är att tillhandahålla produkter och tjänster inom veterinärmedicin jämte därmed förenlig verksamhet.
Address
Tulegatan 12
Email
jakob.christiernin@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 796 | 1 161 | 439 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 65 | 129 | −90 | −61 | −14 |
| Depreciation & amort. | −22 | −22 | −5 | −5 | −0 |
| EBIT | 43 | 107 | −95 | −66 | −14 |
| Net financials | −8 | −5 | −2 | — | — |
| Profit before tax | 35 | 102 | −97 | −66 | −14 |
| Tax | −8 | −21 | −0 | −0 | −0 |
| Net profit | 27 | 81 | −97 | −66 | −14 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 486 | 433 | 246 | 103 | 85 |
| Equity | 273 | 304 | 67 | 51 | 52 |
| Long-term debt | 46 | 4 | 0 | 0 | 0 |
| Short-term debt | 167 | 126 | 179 | 52 | 33 |
| Total debt | 213 | 130 | 179 | 52 | 33 |
EBITDA margin
-1400000.0%
This company
15.8%
Market median
-8860859% vs market
20202024
Equity ratio
61.2%
This company
38.2%
Market median
+60% vs market
20202024
Return on equity
-26.9%
This company
18.4%
Market median
-246% vs market
20202024
Net profit margin
-1400000.0%
This company
8.1%
Market median
-17284051% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.63×
This company
0.62×
Market median
+2% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NJ Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
LC Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LillyVet AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lilian Cristina Gomes Christiernin | Chief Executive Officer | 0 companies |
| Nils Jakob Vilhelm Christiernin | Chief Executive Officer | 0 companies |
| Annbritt Mariana Christiernin Lantz | Deputy Board Member | 0 companies |